CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  

TB Facts for Health Care Workers
2006

Selected Bibliography

American Thoracic Society, Centers for Disease Control and Prevention. Treatment of Tuberculosis. MMWR 2003; 52(No. RR-11). www.cdc.gov/mmwr/PDF/rr/rr5211.pdf

American Thoracic Society.  Diagnostic standards and classification of TB in adults and children. Am J Respir Crit Care Med 2000;161:1376‑1395. www.cdc.gov/nchstp/tb/pubs/PDF/1376.pdf

Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005; 54(No. RR-17).
www.cdc.gov/mmwr/pdf/rr/rr5417.pdf

Centers for Disease Control and Prevention. Guidelines for using the Quantiferon®-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005; 54(No. RR-15, 49-55)
www.cdc.gov/mmwr/pdf/rr/rr5415.pdf

Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2003. Atlanta, Ga: U.S. Department of Health and Human Services, CDC; 2004.
www.cdc.gov/nchstp/tb/surv/surv2003/PDF/Surv_Report_2003_small.pdf

Centers for Disease Control and Prevention. Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. 2004. MMWR 2004; 53(No. 02).
www.cdc.gov/nchstp/tb/tb_hiv_drugs/PDF/tbhiv.pdf

Centers for Disease Control and Prevention. Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor-Alpha --- California, 2002—2003. MMWR 2004; 53(No. 30).
www.cdc.gov/mmwr/PDF/wk/mm5330.pdf

Centers for Disease Control and Prevention. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. MMWR 2003; 52(No. 31).
www.cdc.gov/mmwr/PDF/wk/mm5231.pdf

Centers for Disease Control and Prevention. Guidelines for environmental infection control in health-care facilities. MMWR 2003; 52(No. RR-10).
www.cdc.gov/mmwr/PDF/rr/rr5210.pdf

Centers for Disease Control and Prevention. Guidelines for the prevention of opportunistic infections among HIV-infected persons --- 2002. MMWR 2002; 51(No. RR-08).
www.cdc.gov/mmwr/PDF/rr/rr5108.pdf

Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR 2001; 50(No. RR-19).
www.cdc.gov/mmwr/pdf/rr/rr5019.pdf

Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49(No. RR-06).
www.cdc.gov/mmwr/PDF/rr/rr4906.pdf

Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47(No.RR- 20).
www.cdc.gov/mmwr/PDF/rr/rr4720.pdf

Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR 1997; 46(No. RR-15).
www.cdc.gov/mmwr/PDF/rr/rr4615.pdf

Centers for Disease Control and Prevention. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR 1996; 45(No. RR-04).
www.cdc.gov/mmwr/PDF/rr/rr4504.pdf

Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992; 41(No. RR-11).
www.cdc.gov/mmwr/preview/mmwrhtml/00031296.htm

Lambert L, Rajbhandary S, Qualls N, Budnick L, Catanzaro A, Cook S, Daniels-Cuevas L, Garber E, Reves R.  Costs of implementing and maintaining a tuberculin skin test program in hospitals and health departments. Infection Control and Hospital Epidemiology. 2003 Nov;24:814-818.

Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med.1989;320:545-50.

US Department of Health and Human Services.  TB Respiratory Protection Program in Health Care Facilities: Administrator’s Guide. Cincinnati: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1999.  DHHS publication no. (NIOSH) 99-143.
www.cdc.gov/niosh/99-143.html

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333